Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B5UH
|
|||
| Drug Name |
ALX-0761
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Psoriasis vulgaris [ICD-11: EA90; ICD-9: 696] | Phase 1 | [1] | |
| Company |
Ablynx
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin-17 (IL17) | Target Info | Modulator | [2] |
| Interleukin-25 (IL25) | Target Info | Modulator | [2] | |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Inflammatory bowel disease (IBD) | ||||
| Rheumatoid arthritis | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Interleukin signaling pathway | |||
| Pathway Interaction Database | IL27-mediated signaling events | |||
| IL23-mediated signaling events | ||||
| WikiPathways | TCR Signaling Pathway | |||
| Allograft Rejection | ||||
| IL17 signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02156466) Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects | |||
| REF 2 | Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.